News | Latest Breaking News Stories & Headlines

Cathal Friel co-founded Open Orphan, now know as hVivo, in 2017

hVivo's chairman Cathal Friel not seeking re-election

Irish research and clinical trial specialist hVivo said today that its chairman Cathal Friel does not intend to seek re-election to its board at its AGM later this year.

Business • 10 Apr

Open Orphan tests vaccines and antivirals using human challenge clinical trials

Open Orphan shares at centre of insider trading probe

Specialist pharmaceutical services company Open Orphan says it has been made aware of an allegation of potential insider trading of its shares and is helping the relevant Irish authorities in respect of this allegation.

Business • 15 Sep 22

Open Orphan's executive chairman Cathal Friel

Open Orphan opens two new testing facilities

Specialist pharmaceutical services clinical research company Open Orphan is opening a new primary FluCamp volunteer recruitment screening facility in London and a secondary FluCamp recruitment facility in Manchester.

Business • 08 Mar 22

Open Orphan names its new chief executive

Open Orphan names Khan as new CEO

Specialist pharmaceutical services clinical research company Open Orphan has appointed Yamin 'Mo' Khan as its chief executive with immediate effect.

Business • 24 Feb 22

Cathal Friel is the executive chairman of Open Orphan

Open Orphan's hVIVO wins RSV human challenge study deal

Specialist pharmaceutical services clinical research company Open Orphan said its hVIVO subsidiary has signed a £5.1m contract with a biopharmaceutical company to use its respiratory syncytial virus (RSV) human challenge study model.

Business • 17 Nov 21

Cathal Friel, the executive chairman of Open Orphan

Open Orphan's Venn secures contract renewal deal

Specialist pharmaceutical company Open Orphan said its subsidiary Venn Life Sciences has agreed a contract renewal deal with a major global pharmaceutical client worth £1.5m over two years.

Business • 15 Nov 21

Jeremy Skillington is the CEO of Poolbeg Pharma

Open Orphan's Poolbeg Pharma to list on London's AIM

Pharmaceutical firm Open Orphan has today announced plans to spin out a Dublin-headquartered company focused on infectious diseases, called Poolbeg Pharma.

Business • 17 Jun 21

Cathal Friel, executive chairman of Open Orphan

Open Orphan considers spinning out assets

Specialist pharmaceutical services clinical research company, Open Orphan, is considering a possible spin-out of certain non-core development intellectual property assets.

Business • 13 Apr 21

Cathal Friel, executive chairman at Open Orphan

Volunteers complete 'quarantine phase' of Covid study

Dublin-listed pharmaceutical company Open Orphan has said the first three volunteers have now successfully completed the quarantine phase of their 'Covid-19 characterisation study' with no safety concerns presented and have been discharged from the unit.

Business • 25 Mar 21

Cathal Friel, Open Orphan's executive chairman

Open Orphan agrees Covid contract with UK government

Dublin-listed pharmaceutical company Open Orphan said its subsidary hVIVO has agreed a deal with the UK government to develop a Covid-19 human challenge study model.

Business • 20 Oct 20

Open Orphan wins new £4.3m challenge study deal

Dublin-listed pharmaceutical company Open Orphan has announced a new £4.3m contract to conduct a human viral challenge study using one of its eight traditional challenge study models for another of the global top 10 vaccine companies.

Business • 28 Sep 20

Open Orphan signs €4.4m contract with global company

Pharmaceutical services company, Open Orphan has signed a new contract, valued at €4.4m, with a global pharmaceutical company to provide a respiratory syncytial virus (RSV) human challenge study trial.

Business • 10 Aug 20

Open Orphan agrees contract for Covid-19 vaccine trial

Dublin-listed pharmaceutical company Open Orphan has announced a new contract with Codagenix to conduct a first human trial evaluating safety and immunogenicity of a single-dose Covid-19 vaccine.

Business • 28 Jul 20

Open Orphan agrees option to buy CHIMagents

Dublin-listed pharmaceutical services group Open Orphan has signed an option to buy a company called CHIMagents. The company designs and makes "challenge agents", which are used in pharmaceutical trials.

Business • 15 Jul 20

Open Orphan said it saw unprecedented growth opportunities as pharma focuses funding on Covid-19 and respiratory diseases

Open Orphan develops challenge study model for vaccines

Dublin listed pharmaceutical company Open Orphan has said it is developing the world's first challenge study model to test the effectiveness of a number of Covid-19 vaccines that are in development.

Business • 24 Jun 20